ASN003 / Asana BioSci - LARVOL DELTA

A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors (ESMO 2017) - P1; "ASN003 is a novel small molecule, with uniquely selective and potent inhibition of BRAF, PI3-α and -d kinases. To date, ASN003 was well tolerated at doses up to 120 mg QD and achieved good systemic exposure. Updated and detailed clinical safety/efficacy and PK/PD results will be presented."

Colorectal Cancer • Melanoma • Non Small Cell Lung Cancer

ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors (AACR 2018) - "ASN003 is a novel small molecule, with uniquely selective and potent inhibition of BRAF, PI3K- and - kinases. To date, ASN003 was well tolerated at doses up to 400 mg QD/BID and achieved good systemic exposure. Updated and detailed clinical safety/efficacy and PK/PD results will be presented."

Clinical • P1 data • Colorectal Cancer • Melanoma • Non Small Cell Lung Cancer

Study of ASN003 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=24; Terminated; Sponsor: Asana BioSciences; N=100 ➔ 24; Trial completion date: Dec 2020 ➔ Feb 2019; Active, not recruiting ➔ Terminated; Trial primary completion date: Dec 2020 ➔ Feb 2019; reformulation

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination